InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)
InMed Pharmaceuticals (INM) reported Gross Margin of 22.46% for Q4 2025, down 1900.0% on a YoY basis from 1.25% in Q4 2024, and down 37.6% quarter-over-quarter from 35.99% in Q3 2025.
InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals has reported Gross Margin for 5 years, with the latest figure at 22.46% in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin fell 1900.0% year-over-year to 22.46%; the trailing twelve-month figure through Dec 2025 stood at 29.73% (down 566.0% YoY), and the FY2025 full-year result was 34.53%, up 1058.0% from the prior year.
- Gross Margin for Q4 2025 stood at 22.46%, down from 35.99% in the prior quarter.
- The five-year high for Gross Margin was 67.95% in Q2 2023, with the low at 153.07% in Q3 2022.
- Historically, Gross Margin has averaged 23.38% across 5 years, with a median of 35.99% in 2025.
- The largest YoY upside for Gross Margin was 15542 bps in 2023 against a maximum downside of 4026 bps in 2023.
- InMed Pharmaceuticals' Gross Margin stood at 42.08% in 2021, then sank by 34 bps to 27.92% in 2022, then decreased by 6 bps to 26.14% in 2023, then surged by 59 bps to 41.46% in 2024, then sank by 46 bps to 22.46% in 2025.
- The last three Gross Margin figures came in at 22.46% (Q4 2025), 35.99% (Q3 2025), and 44.2% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -293.83% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 65.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 61.20% |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.46% |
| Sep 30, 2025 | 35.99% |
| Jun 30, 2025 | 44.20% |
| Mar 31, 2025 | 13.92% |
| Dec 31, 2024 | 41.46% |
| Sep 30, 2024 | 39.02% |
| Jun 30, 2024 | 36.32% |
| Mar 31, 2024 | 24.69% |
| Dec 31, 2023 | 26.14% |
| Sep 30, 2023 | 2.36% |
| Jun 30, 2023 | 67.95% |
| Mar 31, 2023 | 18.62% |
| Dec 31, 2022 | 27.92% |
| Sep 30, 2022 | -153.07% |
| Jun 30, 2022 | 48.51% |
| Mar 31, 2022 | 58.88% |
| Dec 31, 2021 | 42.08% |